Editas Medicine, Inc. (0IFK.L)
USD 0.97
(-7.8%)
USD 0.97
(-7.8%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -87.11 Million USD | 10.72% |
| 2022 | -97.57 Million USD | 44.92% |
| 2021 | -177.14 Million USD | -56.01% |
| 2020 | -113.54 Million USD | 45.7% |
| 2019 | -209.1 Million USD | -104.28% |
| 2018 | -102.35 Million USD | 9.58% |
| 2017 | -113.19 Million USD | 24.65% |
| 2016 | -150.22 Million USD | -364.79% |
| 2015 | 56.73 Million USD | 655.57% |
| 2014 | -10.21 Million USD | -10415.15% |
| 2013 | 99 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -25.74 Million USD | 26.63% |
| 2024 Q1 | -35.08 Million USD | 59.72% |
| 2024 Q3 | -57.34 Million USD | -122.76% |
| 2023 Q2 | -183.63 Million USD | -99.85% |
| 2023 Q3 | -47.92 Million USD | 73.9% |
| 2023 Q4 | -87.11 Million USD | -81.77% |
| 2023 FY | -87.11 Million USD | 10.72% |
| 2023 Q1 | -91.88 Million USD | 5.83% |
| 2022 FY | -97.57 Million USD | 44.92% |
| 2022 Q4 | -97.57 Million USD | 48.48% |
| 2022 Q3 | -189.4 Million USD | -26.99% |
| 2022 Q2 | -149.14 Million USD | 20.55% |
| 2022 Q1 | -187.71 Million USD | -5.97% |
| 2021 Q2 | -307.57 Million USD | 5.66% |
| 2021 Q1 | -326.03 Million USD | -187.13% |
| 2021 Q3 | -231.19 Million USD | 24.84% |
| 2021 Q4 | -177.14 Million USD | 23.38% |
| 2021 FY | -177.14 Million USD | -56.01% |
| 2020 Q1 | -205.67 Million USD | 1.64% |
| 2020 Q2 | -457.01 Million USD | -122.21% |
| 2020 Q3 | -252.86 Million USD | 44.67% |
| 2020 FY | -113.54 Million USD | 45.7% |
| 2020 Q4 | -113.54 Million USD | 55.1% |
| 2019 FY | -209.1 Million USD | -104.28% |
| 2019 Q3 | -87.12 Million USD | 54.9% |
| 2019 Q2 | -193.17 Million USD | -38.42% |
| 2019 Q1 | -139.55 Million USD | -36.34% |
| 2019 Q4 | -209.1 Million USD | -140.01% |
| 2018 Q2 | -98.98 Million USD | 46.35% |
| 2018 Q3 | -79 Million USD | 20.18% |
| 2018 FY | -102.35 Million USD | 9.58% |
| 2018 Q4 | -102.35 Million USD | -29.56% |
| 2018 Q1 | -184.48 Million USD | -62.97% |
| 2017 Q3 | -52.87 Million USD | 44.47% |
| 2017 FY | -113.19 Million USD | 24.65% |
| 2017 Q1 | -302.62 Million USD | -101.44% |
| 2017 Q2 | -95.21 Million USD | 68.54% |
| 2017 Q4 | -113.19 Million USD | -114.09% |
| 2016 Q3 | -167.82 Million USD | 13.92% |
| 2016 Q4 | -150.22 Million USD | 10.49% |
| 2016 Q2 | -194.97 Million USD | 10.38% |
| 2016 Q1 | -217.55 Million USD | -483.46% |
| 2016 FY | -150.22 Million USD | -364.79% |
| 2015 Q1 | 10.62 Million USD | 204.02% |
| 2015 FY | 56.73 Million USD | 655.57% |
| 2015 Q4 | 56.73 Million USD | 136.97% |
| 2015 Q3 | -153.47 Million USD | -234.59% |
| 2015 Q2 | -45.87 Million USD | -531.8% |
| 2014 Q4 | -10.21 Million USD | 0.0% |
| 2014 FY | -10.21 Million USD | -10415.15% |
| 2013 FY | 99 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 15.381% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | -179.066% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 143.984% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 373.219% |
| bluebird bio, Inc. | 108.57 Million USD | 180.239% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -866.238% |
| Imunon, Inc. | -4.69 Million USD | -1753.819% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.678% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 104.152% |
| Myriad Genetics, Inc. | 88.1 Million USD | 198.883% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 149.135% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -159.838% |
| Verastem, Inc. | -37.27 Million USD | -133.693% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 101.058% |
| Waters Corporation | 1.96 Billion USD | 104.444% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.325% |
| Biogen Inc. | 6.28 Billion USD | 101.385% |
| Nektar Therapeutics | 210.24 Million USD | 141.436% |
| Perrigo Company plc | 3.32 Billion USD | 102.622% |
| Dynavax Technologies Corporation | 106.63 Million USD | 181.696% |
| Illumina, Inc. | 1.21 Billion USD | 107.176% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 1350.216% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 23.507% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 160.049% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 1312.133% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 123.001% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -1126.986% |
| Evolus, Inc. | 63.7 Million USD | 236.743% |
| Adicet Bio, Inc. | -142 Million USD | 38.654% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | -136.703% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -221.461% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 118.992% |
| FibroGen, Inc. | 56.76 Million USD | 253.462% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 107.608% |
| OPKO Health, Inc. | 230.68 Million USD | 137.764% |
| Homology Medicines, Inc. | 18.43 Million USD | 572.506% |
| Geron Corporation | 14.76 Million USD | 690.177% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 105.495% |
| Exelixis, Inc. | -73.05 Million USD | -19.255% |
| Viking Therapeutics, Inc. | -54.25 Million USD | -60.565% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 42.316% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 21.8% |
| Zoetis Inc. | 4.76 Billion USD | 101.829% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 56.403% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -765.018% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.089% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -497.831% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 108.263% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 108.996% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 35.66% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 106.309% |
| Blueprint Medicines Corporation | 702.83 Million USD | 112.395% |
| Insmed Incorporated | 721.62 Million USD | 112.072% |
| TG Therapeutics, Inc. | 17.86 Million USD | 587.717% |
| Incyte Corporation | -3.17 Billion USD | 97.256% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 111.376% |